Landos Biopharma (LABP) Financials

$22.91

$0.11 (0.50%)

As on 23-May-2024 16:37EDT

Market cap

$72 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

2.1

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Operating Revenue	--	--	--	18.00	18.00	--
Cost of Revenue	--	--	0.58	0.20	0.14	0.10
Gross Profit	--	--	-0.58	18.00	-0.14	-0.10
Operating Expenses	25.24	22.73	40.56	56.82	30.68	13.29
Operating Profit (EBIT)	-25.24	-22.73	-40.56	-38.82	-30.68	-13.29
Other Income	--	--	--	--	--	--
Profit before Tax	-24.80	-21.94	-39.28	-38.42	-30.14	-13.47
Provision for Tax	0.45	--	-1.29	-0.20	-0.08	0.46
Profit after Tax (Net Income)	-24.80	-21.94	-37.99	-38.23	-30.14	-13.93
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-3.92	--	--	-38.42	-30.14	-13.47

Liabilities ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Shareholder's Funds	23.15	31.79	39.13	76.27	-54.02	-25.58
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	3.44	12.91	73.31	73.04
Current Liabilities	6.74	6.25	6.12	16.61	11.03	3.03
Total Liabilities	36.64	38.04	45.25	92.88	30.33	50.48

Assets ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Non-Current Assets	--	--	--	0.73	0.44	0.37
Current Assets	29.90	38.04	45.25	92.15	29.89	50.11
Total Assets	36.64	38.04	45.25	92.88	30.33	50.48
Total Debt*	--	--	--	--	--	--
Net Current Assets	23.15	31.79	39.13	75.54	18.85	47.08

Cashflow ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Cash From Operating Activities	--	-20.48	-45.77	-27.06	-22.96	-9.87
Cash Flow from Investing Activities	--	--	--	-58.71	14.13	-40.33
Cash from Financing Activities	--	13.57	0.62	91.61	1.52	59.65
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Adjusted EPS ($)	-3.99	-3.53	-9.44	-9.50	-7.70	-4.27
Cash EPS ($)	--	-3.53	-9.29	-9.45	-7.66	-4.24
Adjusted Book Value ($)	--	5.12	9.72	18.95	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-3.30	-11.37	-6.72	-5.86	-3.03
Free Cash Flow per Share ($)	--	-3.30	-11.37	-6.83	-5.91	-3.08

Profitability Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
ROCE (%)	--	-61.86	-65.84	-343.56	75.74	113.34
ROE (%)	-81.55	-61.86	-65.84	-343.56	75.74	113.34
ROA (%)	-53.92	-52.67	-55.01	-62.05	-74.60	-52.30
EBIT Margin (%)	--	--	--	-215.64	-170.42	--
Net Margin (%)	--	--	--	-212.37	-167.47	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Revenue Growth (%)	--	--	-1.00	--	--	--
EBIT Growth (%)	66.02	--	-4.50	-26.54	-130.82	-123.96
Net Profit Growth (%)	13.70	42.26	0.61	-26.81	-116.38	-130.49
EPS Growth (%)	39.58	0.63	0.01	-0.23	-0.80	--
Book Value Growth (%)	-48.57	--	--	--	--	--

Valuation Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Price / Earnings	--	-1.04	-0.05	-0.51	--	--
Price / Book Value	2.11	0.71	0.05	0.25	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.29	0.65	1.06	1.85	--	--
Close Price ($)	21.48	3.66	5.00	48.00	--	--
High Price ($)	21.87	6.20	53.40	169.89	--	--
Low Price ($)	2.50	2.33	2.11	45.40	--	--
Market Cap ($ Cr)	71.68	--	--	--	--	--

Solvency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debt to Equity	--	--	--	--	--	--
Short term debt to equity ratio	--	--	--	--	--	--
Current Ratio	4.43	6.09	7.39	5.55	2.71	16.56
Quick Ratio	4.43	--	--	--	2.58	--
Interest Coverage	-13.08	--	-70.30	-94.21	-67.42	-43.72

Operating Efficiency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debtors to sales (%)	--	--	--	--	0.86	--
Asset Turnover	--	--	--	0.29	0.45	--
Receivable days	--	--	--	3.12	1.57	--
Inventory Days	--	--	--	2,605.20	3,727.15	--
Payable days	--	--	5,172.69	20,045.89	14,202.09	6,631.24
Cash Conversion Cycle	--	--	--	-17,437.56	-10,473.37	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.